FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2040-2052 May 17, 2007 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Drazen, J. M. Editorial Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Treatment guidelines recommend the regular use of inhaled corticosteroids for patients with mild persistent asthma. We investigated whether the symptom-driven use of a combination of beclomethasone dipropionate and albuterol (also known as salbutamol) in a single inhaler would be as effective as the regular use of inhaled beclomethasone and superior to the as-needed use of inhaled albuterol.

Methods We conducted a 6-month, double-blind, double-dummy, randomized, parallel-group trial. After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 µg of beclomethasone and 100 µg of albuterol in a single inhaler as needed (as-needed combination therapy); placebo twice daily plus 100 µg of albuterol as needed (as-needed albuterol therapy); 250 µg of beclomethasone twice daily and 100 µg of albuterol as needed (regular beclomethasone therapy); or 250 µg of beclomethasone and 100 µg of albuterol in a single inhaler twice daily plus 100 µg of albuterol as needed (regular combination therapy). The primary outcome was the morning peak expiratory flow rate.

Results In 455 patients with mild asthma who had a forced expiratory volume in 1 second of 2.96 liters (88.36% of the predicted value), the morning peak expiratory flow rate during the last 2 weeks of the 6-month treatment was higher (P=0.04) and the number of exacerbations during the 6-month treatment was lower (P=0.002) in the as-needed combination therapy group than in the as-needed albuterol therapy group, but the values in the as-needed combination therapy group were not significantly different from those in the groups receiving regular beclomethasone therapy or regular combination therapy. The cumulative dose of inhaled beclomethasone was lower in the as-needed combination therapy group than in the groups receiving regular beclomethasone therapy or regular combination therapy (P<0.001 for both comparisons).

Conclusions In patients with mild asthma, the symptom-driven use of inhaled beclomethasone (250 µg) and albuterol (100 µg) in a single inhaler is as effective as regular use of inhaled beclomethasone (250 µg twice daily) and is associated with a lower 6-month cumulative dose of the inhaled corticosteroid. (ClinicalTrials.gov number, NCT00382889 [ClinicalTrials.gov] .)

Source Information

From Università di Ferrara, Ferrara (A.P.); Università di Genova, Genoa (G.W.C.); Università di Padova, Padua (P.M.); Università di Pisa, Pisa (P.P.); Università di Parma (D.O.) and Chiesi Farmaceutici (G.N.) — both in Parma; Università di Pavia, Pavia (E.P.); Università di Catania, Catania (N.C.); Università di Palermo, Palermo (A.M.V.); Contract Research Organization Statistics and Data Management, Verona (P.M.); and Università di Modena, Modena e Reggio Emilia, Modena (L.M.F.) — all in Italy.

Dr. Vignola is deceased.

Address reprint requests to Dr. Fabbri at Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Oncologia, Ematologia e Pneumologia, Università di Modena e Reggio Emilia, Largo del Pozzo, 71-41100 Modena, Italy, or at fabbri.leonardo{at}unimore.it.

Full Text of this Article

This article has been cited by other articles:

• Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., de Jongste, J. C., Kerstjens, H. A. M., Lazarus, S. C., Levy, M. L., O'Byrne, P. M., Partridge, M. R., Pavord, I. D., Sears, M. R., Sterk, P. J., Stoloff, S. W., Sullivan, S. D., Szefler, S. J., Thomas, M. D., Wenzel, S. E., on behalf of the American Thoracic Society/Europea, (2009). An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice. Am. J. Respir. Crit. Care Med. 180: 59-99 [Abstract] [Full Text]  
• Papi, A., Caramori, G., Adcock, I. M., Barnes, P. J. (2009). Rescue Treatment in Asthma: More Than As-Needed Bronchodilation. Chest 135: 1628-1633 [Abstract] [Full Text]  
• Lemanske, R. F. Jr. (2009). Asthma Therapies Revisited: What Have We Learned?. Proc Am Thorac Soc 6: 312-315 [Abstract] [Full Text]  
• Dahlen, B., Lantz, A-S., Ihre, E., Skedinger, M., Henriksson, E., Jorgensen, L., Ekstrom, T., Dahlen, S-E., Larsson, K. (2009). Effect of formoterol with or without budesonide in repeated low-dose allergen challenge. Eur Respir J 33: 747-753 [Abstract] [Full Text]  
• Fanta, C. H. (2009). Asthma. NEJM 360: 1002-1014 [Full Text]  
• Renzetti, G., Silvestre, G., D'Amario, C., Bottini, E., Gloria-Bottini, F., Bottini, N., Auais, A., Perez, M. K., Piedimonte, G. (2009). Less Air Pollution Leads to Rapid Reduction of Airway Inflammation and Improved Airway Function in Asthmatic Children. Pediatrics 123: 1051-1058 [Abstract] [Full Text]  
• Martinez, F. D. (2009). Managing Childhood Asthma: Challenge of Preventing Exacerbations. Pediatrics 123: S146-S150 [Abstract] [Full Text]  
• Rank, M. A., Volcheck, G. W., Li, J. T. C., Patel, A. M., Lim, K. G. (2008). Formulating an Effective and Efficient Written Asthma Action Plan. Mayo Clin Proc. 83: 1263-1270 [Abstract] [Full Text]  
• Sykes, A., Seemungal, T., ICEAD contributors, (2008). Recent advances in exacerbations of asthma. Thorax 63: 758-760 [Full Text]  
• Zervas, E., Oikonomidou, E., Kainis, E., Kokkala, M., Petroheilou, K., Gaga, M. (2008). Review: Control of asthma. Ther Adv Respir Dis 2: 141-148 [Abstract]  
• Sawicki, G. S., Smith, L., Bokhour, B., Gay, C., Hohman, K. H., Galbraith, A. A., Lieu, T. A. (2008). Periodic Use of Inhaled Steroids in Children With Mild Persistent Asthma: What Are Pediatricians Recommending?. CLIN PEDIATR 47: 446-451 [Abstract]  
• Moore, W. C. (2008). Update in Asthma 2007. Am. J. Respir. Crit. Care Med. 177: 1068-1073 [Full Text]  
• Merkus, P J F M (2008). Mould eradication and asthma. Thorax 63: 385-385 [Full Text]  
• Grippi, M. A., Mulrow, C. (2007). Trials That Matter: Minimizing Treatment of Mild, Persistent Asthma. ANN INTERN MED 147: 344-345 [Full Text]  
• O'Byrne, P. M. (2007). How much is too much? The treatment of mild asthma. Eur Respir J 30: 403-406 [Full Text]  
• Merkus, P. J.F.M., Terracciano, L., Fiocchi, A., Bouygue, G. R., Papi, A., Nicolini, G., Fabbri, L. M. (2007). Beclomethasone and Albuterol in Mild Asthma. NEJM 357: 506-507 [Full Text]  
• Fredenburgh, L. E., Campion, E. W., Drazen, J. M. (2007). Mild Persistent Asthma -- Polling Results. NEJM 357: 179-180 [Full Text]  
• Drazen, J. M., Campion, E. W., Curfman, G. D., Miller, P. W., Anderson, K. R., Morrissey, S. (2007). Clinical Decisions. NEJM 356: 2093-2093 [Full Text]  
• (2007). Treatment of Mild Persistent Asthma. NEJM 356: 2096-2100 [Full Text]  
• (2007). Reducing the Intensity of Treatment in Mild Asthma. JWatch General 2007: 1-1 [Full Text]